Certainly using this approach tiling across TP53, mutations of which are enriched in patients with metastatic disease, we were able to identify ctDNA in just under 12% of patients, where it again was associated with the development of metastatic disease. The gene discussed is TP53; the disease is metastatic neoplasm.